
Figures

6.1	Gross expenditures on research and development (GERD) as a proportion of GDP and GERD expenditure in billions of US dollars (PPP), 2009	61
6.2	Evolution of competitive advantage in healthcare	63
9.1	The core and extended accounting framework of SHA 2011	93
9.2	The treatment of imports under SHA	99
11.1	Framework for conceptualizing factors influencing impact of medical travel upon local health system equity	115
14.1	Distribution of MTFs based on their country or region of origin	142
14.2	Distribution of numbers of destination countries	145
14.3	Percentage of firms which advertise various treatments	146
14.4	Percentage of firms which advertise management information	149
25.1	EU mechanisms (based on Council Regulation (EC) No. 1408/71) by which individuals can obtain health care in another Member State	259
33.1	Number of international patients receiving healthcare services in Turkey by year, 2012	333
38.1	The medical tourism industry	384
38.2	Medical tourism and continuity of care	385
41.1	Numbers of organ donors, transplants performed and patients on the waiting list in the US, 2000–2012	412
43.1	Motivations of bariatric tourists	436
44.1	Countries visited	446